{ "docId": "019de516-01ce-701d-bd9b-acac15fa9fab", "docSlug": "a13be9775a99db49a0c5c2ac3ee2ea88", "documentTitle": "Oculis | Investor Conference Presentation Deck | 39 slides", "authorId": "oculis", "authorName": "Oculis", "documentKindSlug": "conference-presentation", "documentKindLabel": "Conference presentation", "sourceTypeSlug": "investor_relations", "sourceTypeLabel": "Investor relations", "presentationDate": "2023-06-01 00:00:00", "orientation": "landscape", "aspectRatio": 1.7777778, "pageNumber": 10, "pageCount": 39, "prevPage": 9, "nextPage": 11, "slideType": "propose_solution", "function": "propose_solution", "density": "overcrowded", "nDataPoints": 10, "notes": null, "elementsJson": null, "metadataConfidence": 0.9, "imagePath": null, "slideHref": "/slides/019de516-01ce-701d-bd9b-acac15fa9fab/10", "deckHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab", "deckJsonHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab.json", "deckAnchorHref": "/decks/019de516-01ce-701d-bd9b-acac15fa9fab#slide-10", "components": [ { "bbox": { "h": 0.35, "w": 0.14, "x": 0.81, "y": 0.39 }, "kind": "chart", "text": "Mean Change in CST From Baseline (µm)\n-23.1\n-77.4\nVehicle (n = 15)\nOCS-01 (n = 45)", "attrs": null, "subkind": "bar-vertical", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "a011c9ac-694d-41fc-bdf5-0351918b1188", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.35, "w": 0.14, "x": 0.67, "y": 0.39 }, "kind": "chart", "text": "Mean Change in BCVA From Baseline\n0.9\n3.8\nVehicle (n = 14)\nOCS-01 (n = 45)", "attrs": null, "subkind": "bar-vertical", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "c924f31b-d107-46a4-b73a-427ff3c123c2", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.21, "w": 0.24, "x": 0.084, "y": 0.35 }, "kind": "image", "text": "OPTIREACH® Formulation Technology", "attrs": null, "subkind": "illustration", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "8b5012a6-7afa-42f2-ba19-267e3d52ca93", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.47, "w": 0.26, "x": 0.387, "y": 0.325 }, "kind": "list", "text": "DME Exploratory 1²\n19 pts Tanito Study successfully completed\nDME Exploratory 2³\n22 pts Ohira Study successfully completed\nDME Phase 2⁴ 144 pts Randomized & double-masked successfully completed", "attrs": null, "subkind": "bullet", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "e0d45da1-b4b2-4783-8648-fa99f311c3d6", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.06, "w": 0.285, "x": 0.044, "y": 0.689 }, "kind": "paragraph", "text": "Ozurdex®, an IVT implant of dexamethasone, is FDA-approved for DME and annualizing at $460M and 7% growth¹", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "002e73e1-6cd8-4169-a86d-1d6897cb8f11", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.033, "w": 0.26, "x": 0.69, "y": 0.229 }, "kind": "paragraph", "text": "Phase 3 program initiated after positive Phase 2 results & EoP2 meeting", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "04937988-7c25-4bba-990d-0d37f1b15a99", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.033, "w": 0.26, "x": 0.387, "y": 0.229 }, "kind": "paragraph", "text": "Positive results in exploratory and Phase 2 studies in DME", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "34425eda-3c7b-4f7f-8aeb-9141d72db2d3", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.04, "w": 0.285, "x": 0.044, "y": 0.28 }, "kind": "paragraph", "text": "OCS-01: High-concentration OPTIREACH® formulation of dexamethasone (15 mg/ml)", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "8f4f1e53-ab44-415a-a3b0-437299ea8ce8", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.04, "w": 0.26, "x": 0.69, "y": 0.28 }, "kind": "paragraph", "text": "Change in BCVA & CST in Phase 2 Trial (Same Patient Population as Ph 3 DIAMOND Trial)", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "a9a7da80-aea2-4bbe-8e43-a549ad8000f0", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.033, "w": 0.289, "x": 0.04, "y": 0.229 }, "kind": "paragraph", "text": "Unique product candidate with clinically validated MoA", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "f9a314d8-4c4d-46ed-a73f-f717b7158b5f", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.105, "w": 0.72, "x": 0.026, "y": 0.87 }, "kind": "source-note", "text": "1. Abbvie Q1 2023 earnings report\n2. Investigator-initiated, open-label, single-center study. Tanito M, et al. Invest Ophthalmol Vis Sci. 2011;52:7944-7948\n3. Ohira A, et al. Acta Ophthalmologica. 2015;93:610-615. Ohira A, et al. Acta Ophthalmologica. 2015;93:610-615.\n4. DME Phase 2: Note: Data presented at Angiogenesis, Exudation and Degeneration, 2020 by KOL (Dugel P.)\n5. Dugel PU. The Oculis OCS-01 phase 1/2 study: an effective topical therapeutic for DME. Presented at: Angiogenesis, Exudation, and Degeneration 2020; Feb. 8, 2020; Miami\nCentral macular thickness (CMT); Best-corrected visual acuity (BCVA)\nvisual acuity (BCVA); Dugel PU. The Oculis OCS-01 phase 1/2 study: an effective topical therapeutic for DME. Presented at: Angiogenesis, Exudation, and Degeneration 2020; Feb. 8, 2020; Miami.", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "71ac7d96-014c-43cc-9df4-e76498ba790c", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.019, "w": 0.74, "x": 0.026, "y": 0.08 }, "kind": "title", "text": "OCS-01 shown to be superior to vehicle on BCVA and CST endpoints in Phase 2 trial", "attrs": null, "subkind": "action-title", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "8acb24ff-53eb-44d6-b5c6-3c9f09c06f35", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.03, "w": 0.429, "x": 0.026, "y": 0.046 }, "kind": "title", "text": "OCS-01 | First Eye Drop for DME", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "3c1fd4c1-941a-4563-84db-0becb8f0b77a", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 16, "from": 10, "beatId": "912bef89-3aea-45e9-87d5-3a2c6a5b8187", "arcName": "The Consultant's Gambit", "arcSlug": "consultants-gambit", "beatName": "Evidence & Proof", "beatSlug": "consultants-gambit-evidence-proof", "evidence": "Slides 10-16 present data and results for OCS-01 in DME.", "position": 2, "confidence": 0.8, "parentBeatName": "Evidence", "parentBeatSlug": "evidence" } ], "loops": [ { "to": 16, "from": 10, "name": "Hypothesis Test", "slug": "42-hypothesis-test", "bestFor": "Strategy validation, due diligence, research presentations", "matchId": "10d012c4-eada-47a2-8cbd-e97bee6ca528", "evidence": "Slides 10-16 provide evidence and proof for OCS-01's effectiveness.", "position": 2, "objective": "Present data and results for OCS-01 in DME", "structure": "The Hypothesis -> Test 1 (Supports/Refutes) -> Test 2 (Supports/Refutes) -> Conclusion (Validated/Pivoted)", "confidence": 0.8, "description": "State a hypothesis upfront, then systematically prove or disprove it with evidence" } ], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }